XORTX Therapeutics Correlations
XRTX Stock | USD 1.00 0.06 5.66% |
The current 90-days correlation between XORTX Therapeutics and Quoin Pharmaceuticals Ltd is 0.27 (i.e., Modest diversification). The correlation of XORTX Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
XORTX Therapeutics Correlation With Market
Average diversification
The correlation between XORTX Therapeutics and DJI is 0.1 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding XORTX Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
XORTX |
Moving together with XORTX Stock
0.72 | EQ | Equillium | PairCorr |
0.83 | ME | 23Andme Holding | PairCorr |
0.79 | VALN | Valneva SE ADR | PairCorr |
0.62 | DNLI | Denali Therapeutics | PairCorr |
0.72 | DNTH | Dianthus Therapeutics | PairCorr |
0.63 | DOMH | Dominari Holdings | PairCorr |
0.76 | DRRX | Durect | PairCorr |
0.78 | DTIL | Precision BioSciences | PairCorr |
0.78 | VIGL | Vigil Neuroscience | PairCorr |
0.81 | VINC | Vincerx Pharma | PairCorr |
0.74 | VKTX | Viking Therapeutics | PairCorr |
0.71 | VRCA | Verrica Pharmaceuticals | PairCorr |
0.77 | VRDN | Viridian Therapeutics Buyout Trend | PairCorr |
0.63 | VRPX | Virpax Pharmaceuticals | PairCorr |
Moving against XORTX Stock
0.83 | VCEL | Vericel Corp Ord | PairCorr |
0.74 | VCYT | Veracyte Potential Growth | PairCorr |
0.66 | DRTS | Alpha Tau Medical | PairCorr |
0.63 | DMAC | DiaMedica Therapeutics | PairCorr |
0.52 | CDIOW | Cardio Diagnostics | PairCorr |
0.52 | SABSW | SAB Biotherapeutics | PairCorr |
0.73 | DVAX | Dynavax Technologies | PairCorr |
0.68 | DYAI | Dyadic International | PairCorr |
0.68 | VRNA | Verona Pharma PLC | PairCorr |
0.58 | VSTM | Verastem | PairCorr |
0.53 | SRZNW | Surrozen Warrant | PairCorr |
0.43 | VTRS | Viatris | PairCorr |
0.42 | KTTAW | Pasithea Therapeutics | PairCorr |
0.36 | VYNE | Vyne Therapeutics | PairCorr |
0.31 | VTVT | vTv Therapeutics | PairCorr |
Related Correlations Analysis
0.29 | 0.19 | 0.57 | -0.17 | CNTX | ||
0.29 | 0.13 | 0.13 | 0.41 | NRSN | ||
0.19 | 0.13 | 0.19 | -0.62 | BTTX | ||
0.57 | 0.13 | 0.19 | -0.23 | QNRX | ||
-0.17 | 0.41 | -0.62 | -0.23 | ENSC | ||
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between XORTX Stock performing well and XORTX Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze XORTX Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
CNTX | 3.76 | (0.90) | 0.00 | 7.08 | 0.00 | 11.01 | 28.09 | |||
NRSN | 4.17 | 0.19 | 0.02 | (0.11) | 4.89 | 12.24 | 31.95 | |||
BTTX | 4.55 | (0.77) | 0.00 | 0.84 | 0.00 | 12.64 | 36.53 | |||
QNRX | 6.71 | 0.66 | 0.10 | 1.48 | 5.79 | 27.27 | 74.46 | |||
ENSC | 12.39 | 3.52 | 0.36 | (0.82) | 8.56 | 26.55 | 189.26 |
XORTX Therapeutics Corporate Management
MD MBA | Chief Officer | Profile | |
Charlotte May | Corporate Secretary | Profile | |
MRCP MD | Chief Officer | Profile | |
David MacDonald | Consultant Operations | Profile | |
Nick Rigopoulos | Director Communications | Profile | |
Allen Davidoff | CEO, Founder | Profile |